{"id":3888,"date":"2025-03-31T18:11:52","date_gmt":"2025-03-31T18:11:52","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/dacarbazine-txt\/"},"modified":"2025-03-31T18:11:52","modified_gmt":"2025-03-31T18:11:52","slug":"dacarbazine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/dacarbazine-txt\/","title":{"rendered":"Dacarbazine.txt"},"content":{"rendered":"

Dacarbazine<\/h1>\n

CLINICAL USE <\/H3>
\nAntineoplastic agent:Metastatic melanoma Hodgkin\u2019s disease Soft tissue sarcomas

DOSE IN NORMAL RENAL FUNCTION <\/H3>Single agent: 2\u20134.5 mg\/kg daily for 10 days, repeated every 4 weeks or 200\u2013250 mg\/m2 daily for 5 days, repeated every 3 weeks or 850 mg\/m2 on day 1 then once every 3 weeksHodgkin\u2019s disease: 150 mg\/m 2 daily for 5 days, repeated every 4 weeks (or 375 mg\/m2 every 15 days in combination)

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :182.2<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :0\u20135<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
  • 20 to 50 &nbsp &nbsp :<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :1.49<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :0.5\u20135\/Increased

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>45\u201360 80% of dose30\u201345 75% of dose<30 70% of dose, use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Likely dialysability. Dose as in GFR<30 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Likely dialysability. Dose as in GFR<30 mL\/min
  • HDF\/high flux &nbsp :Likely dialysability. Dose as in GFR<30 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Likely dialysability. Dose as in GFR<30 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>10 mL water for injection per 100 mg vial (50 mL for 1 g vial)

    Route <\/H4>IV

    Rate of Administration <\/H4>Bolus: 1\u20132 minutes Infusion: 15\u201330 minutes

    Comments<\/H4>For infusion can be diluted with up to 125\u2013300 mL glucose 5% or sodium chloride 0.9%Avoid contact with skin and mucous membranesProtect from light Doses above 200 mg\/m 2 should be given as infusions

    OTHER INFORMATION <\/H4>Nadir for white cell count usually occurs 21\u201325 days after a doseDacarbazine (DTIC) is assumed to be inactive. Microsomal metabolism in the liver produces main metabolite; 5-aminoimidazole-4-carboxamide (AIC). Approximately 50% DTIC is renally cleared. Half of this is unchanged DTIC and approximately 50% is AIC. DTIC is secreted via the renal tubules, rather than filtered at the glomerulus Doses from Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.
    \n","protected":false},"excerpt":{"rendered":"

    Dacarbazine CLINICAL USE Antineoplastic agent:Metastatic melanoma Hodgkin\u2019s disease Soft tissue<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3888","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3888"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3888\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}